Oncolytics Biotech financials
$0.6745+1.73%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$28.7M | -$25.5M | -$25.5M | -$19.8M | -$20.8M | -$20.0M | -$15.7M | -$12.7M | -$12.4M | -$11.4M |
| Net income | -$28.8M | -$22.8M | -$20.9M | -$18.3M | -$20.8M | -$17.7M | -$25.5M | -$12.6M | -$12.4M | -$11.3M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.30 | $-0.30 | $-0.31 | $-0.32 | $-0.39 | $-0.44 | $-1.15 | $-0.78 | $-0.89 | $-0.89 |
| EBITDA | -$28.7M | -$25.5M | -$25.4M | -$19.8M | -$20.7M | -$19.9M | -$15.6M | -$12.7M | -$12.3M | -$11.3M |
| Operating cash flow | -$20.1M | -$19.9M | -$21.5M | -$17.2M | -$17.7M | -$17.3M | -$15.3M | -$8.8M | -$11.8M | -$9.3M |
| Free cash flow | -$20.1M | -$20.1M | -$21.5M | -$17.3M | -$17.7M | -$17.4M | -$15.3M | -$8.9M | -$11.9M | -$9.3M |
| Diluted shares | 95.9M | 76.5M | 67.6M | 58.0M | 53.5M | 40.3M | 22.1M | 16.0M | 13.9M | 12.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.2M | $11.1M | $26.3M | $8.6M | $32.6M | $24.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $15.1M | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $7.6M | $13.4M | $29.3M | $27.5M | $36.3M | $27.0M |
| Total liabilities | $11.4M | $10.1M | $8.5M | $8.0M | $7.7M | $7.5M |
| Shareholders' equity | -$3.8M | $3.3M | $20.8M | $19.5M | $28.6M | $19.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology